SwanBio Therapeutics Email Format
Biotechnology ResearchPennsylvania, United States11-50 Employees
SwanBio is now part of Spur Therapeutics. Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more at spurtherapeutics.com.